Schaeffer's Top Stock Picks for '25

Kite Pharma Inc (KITE) Leaves Bears (and Bulls) Reeling After Earnings

Analysts and short sellers are reconsidering their extreme positions on Kite Pharma Inc (KITE) after earnings

Mar 1, 2016 at 3:02 PM
facebook X logo linkedin


Biopharmaceutical firm Kite Pharma Inc (NASDAQ:KITE) reported a slimmer-than-predicted fourth-quarter loss after Monday's close, sending the shares soaring higher -- up 14.5% at $51.20 this afternoon. In the wake of last night's earnings report, both traders and analysts have scrambled to adjust their expectations on KITE stock.

On the charts, KITE touched an all-time high of $89.84 last November -- but the stock then quickly plummeted to an annual low of $38.41 last month, shedding more than 57% of its value from peak to trough. And since early February, KITE shares have repeatedly been rejected by resistance in the $51 area.

In light of the stock's rapid plunge, short sellers have heavily targeted KITE. Short interest rose more than 9% in the last two-week reporting period -- and now accounts for nearly 15% of the stock's total available float. At KITE's average daily volume, it would take about a week for short sellers to buy back all of these shorted shares.

While today's post-earnings pop suggests that some of the shorts may already be stampeding for the exits, it's worth noting that KITE is now staring down its 50-day moving average. Currently located at $51.75, this trendline lies just north of existing resistance near $51, as well as KITE's intraday peak today of $51.60. If the shares back down from this tough technical test, it could embolden more shorts to keep piling on.

On the other end of the sentiment spectrum, analysts were unanimously bullish on KITE ahead of last night's earnings report. Every analyst covering the stock currently gives KITE the equivalent of a "strong buy" rating. However, this morning, analysts at Jefferies, Goldman Sachs, Canaccord Genuity, and Stifel all cut their price targets on the security -- suggesting KITE's quarterly performance didn't quite live up to this group's high hopes. Any downgrades or additional bearish notes could apply fresh pressure to Kite Pharma Inc (NASDAQ:KITE) in the days and weeks ahead.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

 
 

Which of These SUB-$5 Stocks Could 26x From Here? (AD)

He called a rare 11x on Tesla…

Then he called a 26x on Workhorse…

Then an even rarer 35x on Nio Inc…

Now Tim Bohen says these 5 tiny “America First” stocks are next up in 2025.

They’re trading for less than $5 right now.

But thanks to Elon & Trump’s new alliance…

They could be off to the races in Trump’s first 100 days.

And right now for a limited time…

You can get the names & tickers for just $1 here. (AD)

10 Stock Picks FREE
 
 

Featured Articles from Trusted Partners:

🚀 One Stock Pick Could Change Everything in 2025
What if one stock pick could define your success next year? Get 10 expert-vetted stocks set for 2025—plus 5 bonus picks to watch now. Get the Report →

🆕 New Options Need New Trading Strategies
Zero-DTE options are the newest (and hottest) options to trade.  Professional traders have rushed into the market and are making a mint.  Don’t get left behind - learn all about these options, how to trade them, market setups to profit from, plus much more. Download now →

👀 Revealed: 3 Defensive Stocks for Your Portfolio
Worried about the market? This free report reveals 3 under-the-radar defensive stocks for uncertain times in any kind of economy.

 

 
 

FREE Report Download

 

Follow us on X, Follow us on Twitter